| 1. |
- Richards, A. M. S., et al.
(författare)
-
ALMA sub-mm maser and dust distribution of VY Canis Majoris
- 2014
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 572
-
Tidskriftsartikel (refereegranskat)abstract
- Aims. Cool, evolved stars have copious, enriched winds. Observations have so far not fully constrained models for the shaping and acceleration of these winds. We need to understand the dynamics better, from the pulsating stellar surface to similar to 10 stellar radii, where radiation pressure on dust is fully effective. Asymmetric nebulae around some red supergiants imply the action of additional forces. Methods. We retrieved ALMA Science Verification data providing images of sub-mm line and continuum emission from VY CMa. This enables us to locate water masers with milli-arcsec accuracy and to resolve the dusty continuum. Results. The 658, 321, and 325 GHz masers lie in irregular, thick shells at increasing distances from the centre of expansion. For the first time this is confirmed as the stellar position, coinciding with a compact peak offset to the NW of the brightest continuum emission. The maser shells overlap but avoid each other on scales of up to 10 au. Their distribution is broadly consistent with excitation models but the conditions and kinematics are complicated by wind collisions, clumping, and asymmetries.
|
|
| 2. |
- Robishaw, T., et al.
(författare)
-
Measuring magnetic fields near and far with the SKA via the zeeman effect
- 2014
-
Ingår i: Proceedings of Science. - 1824-8039. ; 9-13-June-2014
-
Konferensbidrag (refereegranskat)abstract
- The measurement of Zeeman splitting in spectral lines-both in emission and absorption-can provide direct estimates of the magnetic field strength and direction in atomic and molecular clouds, both in our own MilkyWay and in external galaxies. This method will probe the magnetic field in the warm and cold neutral components of the interstellar medium, providing a complement to the extensive SKA Faraday studies planning to probe the field in the ionized components.
|
|
| 3. |
- Ueta, T., et al.
(författare)
-
The Herschel Planetary Nebula Survey (HerPlaNS) I. Data overview and analysis demonstration with NGC 6781
- 2014
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 565, s. A36-
-
Tidskriftsartikel (refereegranskat)abstract
- Context. This is the first of a series of investigations into far-IR characteristics of 11 planetary nebulae (PNe) under the Herschel Space Observatory open time 1 program, Herschel Planetary Nebula Survey (HerPlaNS). Aims. Using the HerPlaNS data set, we look into the PN energetics and variations of the physical conditions within the target nebulae. In the present work, we provide an overview of the survey, data acquisition and processing, and resulting data products. Methods. We performed (1) PACS/SPIRE broadband imaging to determine the spatial distribution of the cold dust component in the target PNe and (2) PACS/SPIRE spectral-energy-distribution and line spectroscopy to determine the spatial distribution of the gas component in the target PNe. Results. For the case of NGC 6781, the broadband maps confirm the nearly pole-on barrel structure of the amorphous carbon-rich dust shell and the surrounding halo having temperatures of 26-40 K. The PACS/SPIRE multiposition spectra show spatial variations of far-.IR lines that reflect the physical stratification of the nebula. We demonstrate that spatially resolved far-IR line diagnostics yield the (T-e, n(e)) profiles, from which distributions of ionized, atomic, and molecular gases can be determined. Direct comparison of the dust and gas column mass maps constrained by the HerPlaNS data allows to construct an empirical gas-to-dust mass ratio map, which shows a range of ratios with the median of 195 +/- 110. The present analysis yields estimates of the total mass of the shell to be 0.86 M-circle dot, consisting of 0.54 M-circle dot of ionized gas, 0.12 M-circle dot of atomic gas, 0.2 M-circle dot of molecular gas, and 4 x 10(-3) M-circle dot of dust grains. These estimates' also suggest that the central star of about 1.5 M-circle dot initial mass is terminating its PN evolution onto the white dwarf cooling track. Conclusions. The HerPlaNS data provide various diagnostics for both the dust and gas components in a spatially resolved manner. In the forthcoming papers of the HerPlaNS series we will explore the HerPlaNS data set fully for the entire sample of 11 PNe.
|
|
| 4. |
- Ueta, T., et al.
(författare)
-
Herschel Planetary Nebula Survey (HerPlaNS)
- 2014
-
Ingår i: Asymmetrical Planetary Nebulae VI conference, Proceedings of the conference held 4-8 November, 2013. ; , s. 106-
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- The Herschel Planetary Nebula Survey (HerPlaNS) is one of the largest Open Time programs carried out by the Herschel Space Observatory, by which we simultaneously probe the dust and gas components of the circumstellar environments of evolved stars. HerPlaNS is part of a community-wide panchromatic (from X-ray to Radio) observational initiative to furnish substantial PN data resources that would allow us - PN astronomers - to tackle a multitude of issues in PN physics. In this contribution we will give a general overview of the survey and a glimpse of what the data can tell us using NGC 6781 as an example.
|
|
| 5. |
- Ueta, T., et al.
(författare)
-
Planetary Nebula dust haloes revealed by Herschel
- 2013
-
Ingår i: Proceedings of Science. - Trieste, Italy : Sissa Medialab. - 1824-8039.
-
Konferensbidrag (refereegranskat)abstract
- Herschel Planetary Nebula Survey (HerPlaNS) is a far-IR imaging and spectroscopic survey of planetary nebulae, performedwith the Herschel Space Observatory, aiming at (1) establishing the spatially-resolved far-IR characteristics of the target nebulae and (2) understanding the energetics and shaping history of the circumstellar nebulae. Below we briefly demonstrate the breadth and depth of the HerPlaNS data set using one of the targets, NGC6781, as an example, and explore expectations in the era of SPICA, the next-generation far-IR mission.
|
|
| 6. |
- Aleman, I., et al.
(författare)
-
Herschel Planetary Nebula Survey (HerPlaNS) First detection of OH+ in planetary nebulae
- 2014
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 566
-
Tidskriftsartikel (refereegranskat)abstract
- Aims. We report the first detections of OH+ emission in planetary nebulae (PNe). Methods. As part of an imaging and spectroscopy survey of 11 PNe in the far-IR using the PACS and SPIRE instruments aboard the Herschel Space Observatory, we performed a line survey in these PNe over the entire spectral range between 51 mu m and 672 mu m to look for new detections. Results. The rotational emission lines of OH+ at 152.99, 290.20, 308.48, and 329.77 mu m were detected in the spectra of three planetary nebulae: NGC 6445, NGC6720, and NGC 6781. Excitation temperatures and column densities derived from these lines are in the range of 27-47 K and 2 x 10(10)-4 x 10(11) cm(-2), respectively. Conclusions. In PNe, the OH+ rotational line emission appears to be produced in the photodissociation region (PDR) in these objects. The emission of OH+ is observed only in PNe with hot central stars (T-eff > 100 000 K), suggesting that high-energy photons may play a role in OH+ formation and its line excitation in these objects, as seems to be the case for ultraluminous galaxies.
|
|
| 7. |
- Nijboer, Cora H, et al.
(författare)
-
Targeting the p53 pathway to protect the neonatal ischemic brain.
- 2011
-
Ingår i: Annals of neurology. - : Wiley. - 1531-8249 .- 0364-5134.
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: To investigate whether inhibition of mitochondrial p53 association using pifithrin-μ (PFT-μ) represents a potential novel neuroprotective strategy to combat perinatal hypoxic-ischemic (HI) brain damage. METHODS: Seven-day-old rats were subjected to unilateral carotid artery occlusion and hypoxia followed by intraperitoneal treatment with PFT-μ, an inhibitor of p53 mitochondrial association or PFT-α an inhibitor of p53 transcriptional activity. Cerebral damage, sensorimotor and cognitive function, apoptotic pathways (cytosolic cytochrome c, Smac/DIABLO, active caspase 3), and oxidative stress (lipid peroxidation and PARP-1 cleavage) were investigated. RESULTS: PFT-μ treatment completely prevented the HI-induced increase in mitochondrial p53 association at 3 hours and reduced neuronal damage at 48 hours post-HI. PFT-μ had long-term (6-10 weeks post-HI) beneficial effects as sensorimotor and cognitive outcome improved and infarct size was reduced by ∼79%. Neuroprotection by PFT-μ treatment was associated with strong inhibition of apoptotic pathways and reduced oxidative stress. Unexpectedly, PFT-μ also inhibited HI-induced upregulation of p53 target genes. However, the neuroprotective effect of inhibiting only p53 transcriptional activity by PFT-α was significantly smaller and did not involve reduced oxidative stress. INTERPRETATION: We are the first to show that prevention of mitochondrial p53 association by PFT-μ strongly improves functional outcome and decreases lesion size after neonatal HI. PFT-μ not only inhibits mitochondrial release of cytochrome c, but also inhibits oxidative stress. We propose that as a consequence nuclear accumulation of p53 and transcription of proapoptotic target genes are prevented. In conclusion, targeting p53 mitochondrial association by PFT-μ may develop into a novel and powerful neuroprotective strategy. ANN NEUROL 2011;00:000-000.
|
|
| 8. |
- Rizvi, Saiyada N. F., et al.
(författare)
-
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET
- 2012
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 39:3, s. 512-520
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: Positron emission tomography (PET) with Zr-89-britumomab tiuxetan can be used to monitor biodistribution of Y-90-ibritumomab tiuxetan as shown in mice. The aim of this study was to assess biodistribution and radiation dosimetry of 90Y-ibritumomab tiuxetan in humans on the basis of Zr-89-ibritumomab tiuxetan imaging, to evaluate whether co-injection of a therapeutic amount of Y-90-ibritumomab tiuxetan influences biodistribution of Zr-89-ibritumomabtiuxetan and whether pre-therapy scout scans with Zr-89-ibritumomab tiuxetan can be used to predict biodistribution of Y-90-ibritumomab tiuxetan and the dose-limiting organ during therapy. Methods: Seven patients with relapsed B-cell non-Hodgkin's lymphoma scheduled for autologous stem cell transplantation underwent PET scans at 1, 72 and 144 h after injection of similar to 70 MBq Zr-89-ibritumomab tiuxetan and again 2 weeks later after co-injection of 15 MBq/kg or 30 MBq/kg Y-90-britumomab tiuxetan. Volumes of interest were drawn over liver, kidneys, lungs, spleen and tumours. Ibritumomab tiuxetan organ absorbed doses were calculated using OLINDA. Red marrow dosimetry was based on blood samples. Absorbed doses to tumours were calculated using exponential fits to the measured data. Results: The highest Y-90 absorbed dose was observed in liver (3.2 +/- 1.8 mGy/MBq) and spleen (2.9 +/- 0.7 mGy/MBq) followed by kidneys and lungs. The red marrow dose was 0.52 +/- 0.04 mGy/MBq, and the effective dose was 0.87 +/- 0.14 mSv/MBq. Tumour absorbed doses ranged from 8.6 to 28.6 mGy/MBq. Correlation between predicted pre-therapy and therapy organ absorbed doses as based on Zr-89-ibritumomab tiuxetan images was high (Pearson correlation coefficient r=0.97). No significant difference between pre-therapy and therapy tumour absorbed doses was found, but correlation was lower (r=0.75). Conclusion: Biodistribution of Zr-89-ibritumomab tiuxetan is not influenced by simultaneous therapy with Y-90-ibritumomab tiuxetan, and Zr-89-ibritumomab tiuxetan scout scans can thus be used to predict biodistribution and dose-limiting organ during therapy. Absorbed doses to spleen were lower than those previously estimated using In-111-ibritumomab tiuxetan. The dose-limiting organ in patients undergoing stem cell transplantation is the liver.
|
|
| 9. |
- Vermeulen, Robert P, et al.
(författare)
-
Clinical correlates of arterial lactate levels in patients with ST-segment elevation myocardial infarction at admission : a descriptive study
- 2010
-
Ingår i: Critical Care. - : Springer Science and Business Media LLC. - 1364-8535 .- 1466-609X. ; 14:5, s. R164-
-
Tidskriftsartikel (refereegranskat)abstract
- ABSTRACT : INTRODUCTION : Blood lactate measurements can be used as an indicator of hemodynamic impairment and relate to mortality in various forms of shock. Little is known at the moment concerning the clinical correlates of systemic lactate in patients with ST-segment elevation myocardial infarction (STEMI). METHODS : To assess the relation of systemic arterial lactate levels in STEMI patients with clinical correlates at presentation in the catheterization laboratory, we measured arterial lactate levels with a rapid point-of-care technique, immediately following femoral sheath insertion. The study population (n= 1,176) was divided into tertiles with lactate levels ≤1.1 (n = 410), 1.2 to 1.7 (n = 398) and ≥1.8 mmol/l (n = 368). We compared both baseline characteristics and outcome measures of the three lactate groups. RESULTS : Factors independently associated with higher lactate levels were hypotension, heart rate, thrombolysis in myocardial infarction (TIMI) flow 0 to 1, diabetes and non-smoking. Mortality at 30 days in the three groups was 2.0%, 1.5% and 6.5%. The latter group also showed lower blush grades and greater enzymatic infarct sizes. An intra aortic balloon pump (IABP) was used more frequently in patients with higher lactate levels (4.2%, 7.6% and 14.7%). CONCLUSIONS : In STEMI patients, impaired hemodynamics, worse TIMI flow and non-smoking were related to increased arterial lactate levels. Higher lactate levels were independently related with 30-day mortality and an overall worse response to percutaneous coronary intervention (PCI). In particular, acute mortality was related to admission lactates ≥1.8 mmol/L. Point-of-care measurement of arterial lactate at admission in patients with STEMI has the potential to improve acute risk stratification.
|
|
